1	Acute pharmacodynamic responses to sitagliptin:
2	Drug-induced increase in early insulin secretion in oral glucose tolerance test.
3	
4	Amber L. Beitelshees PharmD ¹ Elizabeth A. Streeten MD ¹
5	Zhinous Shahidzadeh Yazdi MD ¹ Hilary B. Whitlatch MD ¹ Braxton D. Mitchell PhD ¹
6	Alan R. Shuldiner MD ¹ May E. Montasser PhD ¹ Simeon I. Taylor MD ¹
7	
8	¹ Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of
9	Maryland School of Medicine, Baltimore, MD 21201, USA
10	Correspondence
11	Amber L. Beitelshees, Pharm D, MPH, Department of Medicine, University of Maryland School
12	of Medicine, Baltimore, MD 21201, USA. Email: abeitels@som.umaryland.edu
13	OR
14	Simeon I. Taylor, MD, PhD, Department of Medicine, University of Maryland School of Medicine,
15	Baltimore, MD 21201, USA. Email: <u>staylor2@som.umaryland.edu</u>
16	Funding information: American Diabetes Association (1-16-ICTS-112) and National Institute of
17	Diabetes and Digestive and Kidney Disease (P30DK072488, P30DK079637, T32DK098107)
18	Trial registration: NCT05762744 (clinicaltrials.gov)
19	Study review and approval: Institutional Review Board of the University of Maryland Baltimore
20	

Aim: DPP4 inhibitors are widely prescribed as treatments for type 2 diabetes. Because drug

21 Abstract

22

23 responses vary among individuals, we initiated investigations to identify genetic variants 24 associated with the magnitude of drug responses. 25 Methods: Sitagliptin (100 mg) was administered to 47 healthy volunteers. Several endpoints were measured to assess clinically relevant responses - including the effect of sitagliptin on 26 glucose and insulin levels during an oral glucose tolerance test (OGTT). 27 28 Results: This pilot study confirmed that sitagliptin (100 mg) decreased the area under the curve 29 for alucose during an OGTT (p=0.0003). Furthermore, sitagliptin promoted insulin secretion 30 during the early portion of the OGTT as reflected by an increase in the ratio of plasma insulin at 30 min divided by plasma insulin at 60 min (T30:T60) from 0.87+/-0.05 to 1.62+/-0.36 mU/L 31 (p=0.04). The magnitude of sitagliptin's effect on insulin secretion (as judged by the increase in 32 33 the T30:T60 ratio for insulin) was correlated with the magnitude of sitagliptin-induced increase in 34 the area under the curve for intact plasma GLP1 levels during the first hour of the OGTT. This 35 study confirmed previously reported sex differences in glucose and insulin levels during an 36 OGTT. Specifically, females exhibited higher levels of glucose and insulin at the 90-180 min time 37 points. However, we did not detect significant sex-associated differences in the magnitude of sitagliptin-induced changes in T30:T60 ratios for either glucose or insulin. 38 Conclusions: T30:T60 ratios for insulin and glucose during an OGTT provide useful indices to 39

40 assess pharmacodynamic responses to DPP4 inhibitors.

42 1 | INTRODUCTION

43 The past two decades have been a golden age for discovery and development of diabetes drugs - including three classes of innovative drugs: dipeptidylpeptidase-4 (DPP4) inhibitors, 44 GLP1 receptor agonists, and sodium-glucose cotransporter-2 (SGLT2) inhibitors ¹. There are at 45 46 least four approved DPP4 inhibitors: sitagliptin, saxagliptin, vildagliptin, and linagliptin¹. 47 Sitagliptin was the first drug in the class to be approved and remains the most widely prescribed dipeptidylpeptidase-4 (DPP4) inhibitor. According to FDA-approved prescribing information, 48 sitagliptin decreases mean HbA1c by 0.7% when administered to type 2 diabetic patients who 49 50 are inadequately controlled with metformin. However, there is substantial inter-individual variation in the magnitude of HbA1c-lowering. While some patients experience very modest 51 HbA1c-lowering, others experience HbA1c-lowering exceeding 1.5%². 52 53 DPP4 inhibitors are not the most efficacious class of diabetes drugs with respect to HbA1c-54 lowering ^{1,3-5}, but they have the most favorable profiles with respect to safety and tolerability. Unlike GLP1 receptor agonists ¹, they do not commonly cause nausea or vomiting. Unlike 55 56 SGLT2 inhibitors ⁶, they are not associated with an increased risks of genital infections or ketoacidosis. Alogliptin is already available as a generic drug. When other DPP4 inhibitors 57 58 experience loss of marketing exclusivity in the relatively near future, DPP4 inhibitors will represent an affordable oral antidiabetic drug that can be prescribed early in the course of type 59 2 diabetes to patients who are not adequately controlled on metformin. In this context, it would 60 be desirable to be able to predict which patients are likely to experience above-average 61 62 glycemic responses to DPP4 inhibitors. For example, if a patient experiences above-average HbA1c-lowering (>0.7%) in response to a DPP4 inhibitor, that degree of glycemic improvement 63 would provide substantial clinical benefit to the patient. According to GoodRx, a one-month 64 supply of sitagliptin (100 mg) costs ~\$550 in the US whereas a one-month supply of generic 65 66 alogliptin (25 mg) is available for ~\$150 (i.e., ~70% lower price). The price of generic DPP4

67	inhibitors is projected to fall to levels comparable to generic sulfonylureas or metformin as a
68	result of competition after sitagliptin and other DPP4 inhibitors experience loss of marketing
69	exclusivity. In light of the high degree of safety and tolerability, generic DPP4 inhibitors have
70	potential to displace generic sulfonylureas and generic pioglitazone in many patients'
71	therapeutic regimens – especially if it becomes possible to identify individual patients likely to
72	experience above-average HbA1c-lowering.
73	This manuscript describes an approach to assess the magnitude of an individual's acute
74	pharmacodynamic response to sitagliptin by analyzing data from an oral glucose tolerance test
75	(OGTT). Whereas sitagliptin does not exert a significant effect on the area under the curve
76	(AUC) for glucose-stimulated insulin secretion, sitagliptin administration shifts the time course of
77	insulin secretion to earlier times. Similarly, sitagliptin significantly alters the time course for
78	glucose levels during an OGTT. These data provide validation for a promising approach to
79	conduct a pharmacogenomic study to identify genetic variants that are associated with
80	pharmacodynamic responses to sitagliptin.

82 2 | METHODS

83 2.1 | Study population: recruitment and screening

84 The Old Order Amish population of Lancaster County, PA emigrated from Central Europe in the 85 early 1700's. University of Maryland School of Medicine researchers have been studying genetic determinants of cardiometabolic health in this population since 1993. To date, ~10.000 86 Amish adults participated in one or more studies as part of the University of Maryland Amish 87 88 Research Program (http://www.medschool.umaryland.edu/endocrinology/Amish-Research-89 Program/). The present study was a sub-study of a pilot study in healthy volunteers in which we investigated pharmacodynamic responses to exenatide (NCT05071898 at clinicaltrials.gov) 7. All 90 procedures were reviewed and approved by the University of Maryland Baltimore Institutional 91 92 Review Board. 93 A research nurse, accompanied by a liaison (a member of the Amish community), made home 94 visits to invite individuals to participate in the study. If individuals expressed interest, the study 95 was explained in detail; potential participants were invited to sign an informed consent form. 96 Thereafter, the research nurse obtained a medical history; measured height, weight, and blood

pressure; and obtained blood samples for screening laboratory tests (hematocrit, fasting plasma

glucose, serum creatinine, serum AST, serum ALT, serum TSH, and HbA1c).

99 2.2 | Study design: overview

97

Participants in the parent clinical trial with exenatide (NCT05762744) were offered the
 opportunity to participate in this clinical trial investigating pharmacodynamic responses to
 sitagliptin. This sub-study was designed as a crossover study in which healthy individuals
 underwent a control oral glucose tolerance test (OGTT). After a washout period of at least one
 week, participants underwent a second OGTT. Two hours prior to the second OGTT,
 participants received sitagliptin (100 mg, p.o.). On the days of the OGTTs, participants were

106 transported to the Amish Research Clinic, in the fasting state, and their heights, weights, and 107 vital signs were measured. Participants were weighed in a standardized manner while wearing a gown. Reproductive age women underwent a pregnancy test to exclude women who were 108 pregnant. Fasting blood tests were obtained to measure fasting plasma glucose and lipid profile. 109 110 OGTTs were conducted as described previously⁸. Two hours after receiving the intervention [either placebo or sitagliptin (100 mg, p.o.)], participants received oral glucose (75 g). Blood 111 samples were obtained at 7 time points: 0, 30, 60, 90, 120, 150, and 180 minutes. 112 2.3 | Eligibility criteria 113

To be eligible to participate in the clinical trial, individuals were required to be of Amish descent, at least 18 years old, and have BMI between 18-40 kg/m². Exclusion criteria are summarized in the Supplementary Appendix.

117 2.4 | Clinical chemistry

Processing of blood samples and laboratory methods are summarized in the SupplementaryAppendix.

120 2.5 | Data and statistical analyses

121 We established two primary end points: sitagliptin's effect on area under the curve (AUC) for

levels of (a) insulin and (b) glucose during the course of a 3-hour OGTT. We also established

several secondary endpoints: sitagliptin's effect on AUC for intact GLP1, total GIP, and

124 glucagon during the course of the first hour of an OGTT. After having reviewed the OGTT data,

125 we established six exploratory end-points:

<u>T30:T60 ratio for insulin</u>: the ratio of the insulin level at 30 min divided by the insulin level at
 60 min in both the (a) control OGTT and (b) sitagliptin OGTT.

- <u>T30:T60 ratio for glucose</u>: the ratio of the glucose level at 30 min divided by the glucose
 level at 60 min in both the (c) control OGTT and (d) sitagliptin OGTT.
- 130 *Drug effects*: (e) the ratio of the T30:T60 ratio for insulin in the sitagliptin OGTT divided by
- the T30:T60 ratio for insulin in the control OGTT; and (f) the ratio of the T30:T60 ratio for
- glucose in the sitagliptin OGTT divided by the T30:T60 ratio for glucose in the control OGTT.
- 133 Statistical significance was assessed using two-tailed Student's t-tests for paired data. Although
- a p-value of p<0.05 was defined as the threshold for nominal statistical significance, a more
- stringent threshold (e.g., p<0.001) may be appropriate to account for multiple comparisons.

137 3 | Results

138 3.1 | Disposition and adverse events

Disposition of participants and adverse events are summarized in Fig. S1. Fifty-nine individuals
were enrolled in this clinical trial between June, 2016 - November, 2018. Forty-seven
participants completed oral glucose tolerance tests (OGTT). Research participants' baseline
characteristics are summarized in Table S1.

143 3.2 | Oral glucose tolerance tests: impact of sitagliptin

Sitagliptin decreased the area under the curve (AUC) for glucose by 9% (p=0.0003) but did not 144 145 significantly affect the AUC for insulin (Fig. 1). Nevertheless, sitagliptin appeared to change the shapes of the curves corresponding to time courses for both glucose and insulin - moving the 146 peaks of the curves for both mean glucose and mean insulin from 60 min (control) to 30 min 147 148 (post-sitagliptin). Accordingly, we calculated ratios of the levels of glucose or insulin at 30 min 149 divided by the corresponding levels at 60 min (T30:T60) (Fig. 2AB). Sitagliptin increased the mean T30:T60 ratio for glucose from 0.93±0.02 to 1.11±0.04 (p=0.0005) and the mean T30:T60 150 151 ratio for insulin from 0.87±0.05 to 1.62±0.04 (p=0.04). We hypothesized that drug-induced 152 increases in early insulin secretion at 30 min drive the subsequent decrease in glucose at 60 153 min. This hypothesis is supported by the observation that individual values of the T30:T60 ratio 154 for glucose were correlated with individual values of the T30:T60 ratio for insulin (r=0.70, 155 p<0.0001) (Fig. 2C). We observed substantial inter-individual variation in the magnitudes of sitagliptin's effect on levels of insulin and glucose (Fig. S2). Approximately 30% of participants 156 157 experienced a numerical decrease in the value of the T30:T60 ratio for insulin after receiving 158 sitagliptin. We hypothesize that these small numerical decreases were likely explained by 159 experimental variation rather than a true "paradoxical" effect of sitagliptin. Similarly. 160 approximately 30% of participants experienced a numerical decrease in the value of the

T30:T60 ratio for glucose after receiving sitagliptin. Among the individuals in whom sitagliptin
was accompanied by increased T30:T60 ratios, the maximum drug effects were ~3-fold for
glucose and ~20-fold for insulin.

164 3.3 | Biological variable affecting responses during OGTTs

Sex. Mean plasma levels of both glucose and insulin were higher in females than in males 165 during the later time points in OGTTs (90-180 min) (Fig. 3). This sex difference was observed in 166 both control OGTTs and sitagliptin OGTTs. Sitagliptin significantly increased mean T30:T60 167 168 ratios for glucose in both males and females (p=0.03). Sitagliptin significantly increased the mean T30:T60 ratio for insulin in males (p=0.01). In addition, the numerical value for the mean 169 T30:T60 ratio for insulin was increased by sitagliptin in females (p=0.11). We did not observe 170 significant differences between the magnitude of the drug effects on mean T30:T60 ratios for 171 172 either glucose or insulin (Table S2).

Age. The variance in age accounted for only 3% of the variation in T30:T60 ratios for glucose in
control OGTTs and 14% of the variance in T30:T60 ratios for glucose in sitagliptin OGTTs (Fig.
S3). The variance in age accounted for only 4% of the variation in T30:T60 ratios for insulin in
control OGTTs and 12% of the variance in T30:T60 ratios for insulin in sitagliptin OGTTs (Fig.
S3).

BMI. The variance in BMI accounted for only 4% of the variation in T30:T60 ratios for glucose in control OGTTs and 17% of the variance in T30:T60 ratios for glucose in sitagliptin OGTTs (Fig.
S4). The variance in BMI accounted for only 0.04% of the variation in T30:T60 ratios for insulin in control OGTTs and 0.5% of the variance in T30:T60 ratios for insulin in sitagliptin OGTTs (Fig. S4).

183 3.4 | Impact of sitagliptin on secretion of GLP1, GIP, and glucagon

Sitagliptin increased mean levels of intact GLP1 at all time points (0, 30, and 60 min) 184 and induced a 2.3-fold increase in the mean AUC for intact GLP1 from 7.0±0.7 to 185 15.8 ± 1.5 pmol-hr/L (p=3x10⁻⁸) (Fig. 4A). Sitagliptin increased the mean AUC for 186 glucagon by 66% from 3.74 ± 0.27 to 6.21 ± 0.46 (p=7x10⁻⁹) (Fig. 4C). The increase in 187 mean AUC for glucagon is primarily a reflection of an increase in mean glucagon levels 188 189 at time zero. Sitagliptin did not affect mean total GIP levels at time zero but decreased mean AUC for total GIP by 24% (Fig. 4B). We did not conduct assays that specifically 190 measured levels of intact GIP. 191 192 We hypothesized that drug-induced increases in GLP1 secretion contributed to the drug-induced increase in insulin secretion during the OGTT. This hypothesis is 193 supported by the observation that individual values of the drug-effect on insulin levels 194 were correlated with individual values of the drug effect on GLP1 levels (r=0.29, p=0.04) 195 (Fig. 5). 196

As this clinical trial was a sub-study within our pilot clinical trial of pharmacodynamic 197 responses to exenatide⁷, we inquired whether responses to sitagliptin were correlated 198 with responses to exenatide. Forty-five participants completed both frequently sampled 199 intravenous glucose tolerance tests in our exenatide clinical trial and oral glucose 200 tolerance tests in our sitagliptin clinical trial. The variance in exenatide's effect to 201 202 increase first phase insulin secretion accounted for only 0.7% of the variance in sitagliptin's effect to increase T30:T60 for insulin (r=0.084) (Fig. S5). The variance in 203 exenatide's effect to accelerate the rate of glucose disappearance accounted for only 204 205 0.007% of the variance in sitagliptin's effect to increase T30:T60 for insulin (r=0.0084) (Fig. S5). 206

207

208 4 | Discussion

209 Our clinical trial demonstrated that sitagliptin (100 mg) decreased mean AUC for glucose by 9% 210 when administered to healthy volunteers two hours prior to initiation of an OGTT (Fig. 1). Similarly, Herman et al.⁹ reported that sitagliptin (200 mg) decreased mean weighted averages 211 for *incremental* glucose by 18% when administered to patients with type 2 diabetes two hours 212 before an OGTT. Whereas Herman et al. ⁹ reported that sitagliptin (200 mg) increased mean 213 weighted averages for insulin and C-peptide by ~20% in patients with type 2 diabetes, our 214 215 clinical trial did not detect a significant effect of sitagliptin (100 mg) on mean AUC for insulin in healthy volunteers. Both Herman et al.⁹ and we demonstrated that sitagliptin induced an 216 approximately twofold increase in levels of intact GLP1. Herman et al.⁹ demonstrated that 217 218 sitagliptin increased levels of active GIP while inducing a modest decrease in total levels of GIP. Although we did not measure levels of intact GIP, we confirmed their observation that sitagliptin 219 220 decreased mean AUC for GIP by 24%. As hypothesized by Herman et al., it seems likely that sitagliptin-induced increases in intact GLP1 and/or intact GIP mediate the effect of drug to 221 222 improve glucose tolerance. Whereas Herman et al. ⁹ reported a 14% decrease in glucagon 223 levels, we observed a highly significant 66% increase in mean AUC for glucagon in response to sitagliptin (100 mg). Although it is unclear how to explain the difference between data in healthy 224 225 volunteers versus patients with type 2 diabetes, it is noteworthy that diabetes is associated with 226 dysregulation of glucagon secretion ¹⁰⁻¹². Mathematical modeling of meal tolerance tests 227 demonstrated that vildagliptin increased insulin secretion (primarily in response to breakfast and lunch rather than dinner) without altering glucose sensitivity of the β -cells ^{13,14}. Alsalim et al. ¹⁵ 228 reached similar conclusions when mathematical modeling was applied to analysis of the effect 229 230 of sitagliptin on meal tolerance tests conducted either in healthy volunteers or patients with type 231 2 diabetes. Just as we observed that sitagliptin induced a small effect to decrease mean AUC

for glucose (p=0.0003) without altering mean AUC for insulin in healthy volunteers, Alsalim et al.
similarly observed that sitagliptin decreased mean AUC for glucose by 14% in both healthy
volunteers and patients with type 2 diabetes without inducing a statistically significant effect on
mean AUCs for insulin or C-peptide.

236 How can one explain the apparent paradox that sitagliptin improved glucose tolerance (i.e., 237 significantly decreased the mean AUC for glucose) without increasing mean AUC for insulin? Although sitagliptin (100 mg) did not alter mean glucose levels at 0 or 30 min, sitagliptin 238 239 decreased glucose levels at later time points in the OGTT – most notably at 60 and 90 min. 240 Moreover, although sitagliptin increased mean insulin levels at 30 min, mean insulin levels at 60 min were actually lower for the sitagliptin OGTTs than for the control OGTTs. Mean AUCs were 241 242 unchanged because the lower levels at 60 min are balanced out by higher levels at 30 min. We 243 hypothesize that the increase in early insulin secretion (i.e., at 30 min) may drive the 244 subsequent decrease in mean glucose levels (e.g., at 60 and 90 min). This could be viewed as the mirror image of the natural history of type 2 diabetes, in which early insulin secretion (first 245 phase) is selectively lost early in the natural history of the disease. In that context, a selective 246 increase in early insulin secretion addresses the pathophysiology of type 2 diabetes. Based on 247 248 our observations, we hypothesized that ratios of insulin levels at 30 min divided by insulin levels at 60 min would provide a useful index of the shape of the curves for the time course of insulin 249 secretion. Because sitagliptin increased mean insulin levels at 30 min and decreased mean 250 251 insulin levels at 60 min (Fig. 1B), sitagliptin administration induced a 1.9-fold increase (p=0.04) 252 in the mean T30:T60 ratio for insulin (Fig. 2B). Similarly, because sitagliptin decreased mean glucose levels at 60 min (Fig. 1A), sitagliptin induced a 19% increase (p=0.0005) in the T30:T60 253 254 ratio for glucose (Fig. 2A).

The principal objective of our study was to validate pharmacodynamic endpoints for a future pharmacogenomic study of individual responses to a single administration of sitagliptin. Our

observations suggest that T30:T60 ratios for glucose and insulin would provide sensitive 257 endpoints for such a pharmacogenomic study. Whereas administration of sitagliptin did not 258 259 change the AUC for insulin in an OGTT, sitagliptin elicited a substantial (90%) increase in the mean T30:T60 ratio for insulin. Furthermore, we observed substantial inter-individual variation in 260 261 the magnitude of sitagliptin's effect on T30:T60 ratios – ranging from little or no effect on either 262 T30:T60 ratio to a 175% increase in the T30:T60 ratio for glucose and a >10-fold increase in the T30:T60 ratio for insulin (Fig. 3). Furthermore, the variance in the sitagliptin-induced increase in 263 the T30:T60 ratio for insulin accounted for ~50% of the variance in the sitagliptin-induced 264 increase in the T30:T60 ratio for glucose (Fig. 2) – suggesting that T30:T60 ratios provide 265 physiologically relevant indices of insulin secretion and insulin action. We hypothesize that inter-266 individual variation in insulin sensitivity and/or glucose effectiveness may also contribute to the 267 unexplained variance in the T30:T60 ratio for glucose. Interestingly, we confirmed the previously 268 269 reported sex-associated difference in responses during an OGTT ¹⁶, which was attributed to slower absorption of orally administered glucose in females as compared to males. Thus, it will 270 be important to adjust for sex as a covariate when conducting a GWAS searching for genetic 271 272 variants associated with the response to sitagliptin.

273 Type 2 diabetes is a progressive disease – with the impairment in beta cell insulin secretion becoming more severe over time ^{3,17}. For example, although first line therapy with metformin 274 may provide acceptable metabolic control early in the course of the disease, it is often 275 necessary to add one or more drugs to restore acceptable metabolic control ^{1,3,17,18}. Physicians 276 277 have guite a number of options when selecting a second drug to prescribe for patients who are inadequately controlled on metformin monotherapy – including, DPP4 inhibitors, SGLT2 278 inhibitors, GLP1R agonists, sulfonylureas, and pioglitazone among others ^{1,3,18,19}. 279 280 Pharmacogenomics offers potential to predict each individual's response to specific diabetes 281 drugs – thereby guiding the choice of optimal therapy for each patient. On average, DPP4

282 inhibitors provide slightly less mean HbA1c-lowering than several other classes of diabetes 283 drugs ^{1,3,4}. However, if a physician could predict that an individual patient would experience 284 above average HbA1c-lowering in response to a DPP4 inhibitor, this would increase the attractiveness of the clinical profile for a DPP4 inhibitor for that patient. The impact of a 285 286 precision therapeutics approach would be magnified if it were possible to apply genetic 287 information to compare the predicted efficacies of several drug classes for each individual 288 patient. This logic provides a strong rationale for conducting pharmacogenomic research in the 289 most important classes of diabetes drugs - including, DPP4 inhibitors, SGLT2 inhibitors, and GLP1R agonists ^{1,18,20}. In this context, it is noteworthy that many of our research participants in 290 this clinical trial underwent studies to assess pharmacodynamic responses to both sitagliptin 291 and exenatide. Interestingly, the variance in responses to exenatide accounted for <1% of the 292 293 variance in responses to sitagliptin (Fig. S2). This observation suggests that some patients 294 might experience above average responses to a DPP4 inhibitor but below average responses to a GLP1R agonists. Although a substantial investment will be required to fully realize the 295 296 potential of pharmacogenomics and precision therapeutics, such an approach has the potential 297 to transform the approach to designing therapeutic regimens for patients with type 2 diabetes.

299 AUTHORS' CONTRIBUTIONS

- 300 Conception of the clinical trial and PIs for grants: ALB, SIT
- 301 Acquisition and analysis of data: ALB, H-RC, MEM, EAS, SIT, HBW, ZSY
- 302 Establishment of Old Order Amish genotype database: BDM, ARS
- 303 Preparation of first draft of manuscript: SIT
- 304 *Revising and approving final version of manuscript*: all authors
- 305 Accountability for all aspects of work: ALB and SIT
- 306

308 Competing Interests

- 309 SIT serves as a consultant for Ionis Pharmaceuticals and receives an inventor's share of
- royalties from NIDDK for metreleptin as a treatment for generalized lipodystrophy. ARS is an
- 311 employee of Regeneron Genetics Center. BDM and MEM receive grant support from
- Regeneron Genetics Center. BDM, MEM, EAS, and HBW have received partial salary support
- from funds provided by RGC. ALB, ZSY, and HRC declare no competing interests.

314	FIGURE 1. Sitagliptin decreases area under the curve (AUC) for glucose levels during an oral
315	glucose tolerance test (OGTT). Forty-seven participants underwent a control 3-hour OGTT (75
316	grams of glucose) (depicted by gray circles in panels A and B and gray bars in panels C and D).
317	A second OGTT was conducted one week later. Sitagliptin (100 mg, p.o.) was administered two
318	hours prior to initiating the second 3-hour OGTT (depicted by black squares in panels A and B
319	and black bars in panels C and D). Data on glucose levels are presented in panels A and C.
320	Data on insulin levels are presented in panels B and D. Data are expressed as means ± SEM.
321	p-values (panels C and D) were calculated using a two-tailed Student's t-test for paired data.

322



331 FIGURE 2. Sitagliptin increases early insulin secretion and improves glucose tolerance during 332 an OGTT. Data from FIG. 1 were reanalyzed by calculating T30:T60 ratios by dividing the concentrations of glucose (panel A) and insulin (panel B) at 30 min by the corresponding 333 334 concentrations at 60 minutes. Gray bars correspond to data from the control OGTTs (panels A 335 and B); black bars correspond to data from the sitagliptin OGTTs (panels A and B). Data are expressed as means ± SEM. p-values (panels A and B) were calculated using a two-tailed 336 337 Student's t-test for paired data. Panel C depicts a graph of individual values of the logarithms of the T30:T60 ratio for glucose as a function of the logarithms of corresponding T30:T60 ratios for 338 insulin. 339



C Correlation: log-transformed drug effects



340

341

342

FIGURE 3. Sex as a biological variable: sex-differences in responses to oral glucose. Data from Figs. 1A and 1B were re-analyzed after stratification according to the self-identified sex of the participant. Data on glucose levels are plotted in Panel A (control OGTT) and Panel B (Sitagliptin OGTT). Data on insulin levels are plotted in Panel D (Control OGTT) and Panel E (Sitagliptin OGTT). Data from Figs. 2A and 2B were re-analyzed after stratification according to the sex of the participant. Data on T30:T60 ratios for glucose and insulin are plotted in Panels C and F, respectively. Data are presented as means ± SEM. p-values were calculated using a twotailed Student's t-test for paired data.



FIGURE 4. Effects of sitagliptin on areas under the curve (AUC) for levels of intact GLP1, total GIP, and glucagon as a function of time in an oral glucose tolerance test (OGTT). Time courses are depicted for GLP1 (panel A), GIP (panel B), and glucagon (panel C). Areas under the curve are depicted for GLP1 (panel D), GIP (panel E), and glucagon (panel F). Data are expressed as means ± SEM. p-values (panels C and D) were calculated using a two-tailed Student's t-test for paired data.

365



- 367 FIGURE 5. Effects of sitagliptin on insulin secretion are correlated with the magnitude of
- 368 sitagliptin's effects on levels of intact GLP1. Individual values of the logarithm of the T30:T60
- ratio for insulin are plotted as a function of the logarithms of individual values of the effect of
- 370 sitagliptin on the AUC for intact GLP1.



377

378

379

381 **REFERENCES**

- 382 1. Taylor SI, Yazdi ZS, Beitelshees AL. Pharmacological treatment of hyperglycemia in type 2
- diabetes. *J Clin Invest.* 2021;131(2).
- 384 2. Merck. Prescribing information for JANUVIA (sitagliptin).
- 385 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021995s042lbl.pdf.
- 386 Downloaded on October 16, 2023.
- 387 3. Nathan DM, Lachin JM, Balasubramanyam A, et al. Glycemia Reduction in Type 2 Diabetes
- 388 Glycemic Outcomes. *N Engl J Med.* 2022;387(12):1063-1074.
- 389 4. Deng Y, Polley EC, Wallach JD, et al. Emulating the GRADE trial using real world data:
- retrospective comparative effectiveness study. *BMJ*. 2022;379:e070717.
- 391 5. Deng Y, Polley EC, Wallach JD, Herrin J, Ross JS, McCoy RG. Comparative effectiveness
- of second line glucose lowering drug treatments using real world data: emulation of a target
 trial. *BMJ Med.* 2023;2(1):e000419.
- Beitelshees AL, Leslie BR, Taylor SI. Sodium-Glucose Cotransporter 2 Inhibitors: A Case
 Study in Translational Research. *Diabetes*. 2019;68(6):1109-1120.
- 396 7. Taylor SI, Montasser ME, Yuen AH, et al. Acute pharmacodynamic responses to exenatide:
- 397 Drug-induced increases in insulin secretion and glucose effectiveness. *Diabetes Obes* 398 *Metab.* 2023;25(9):2586-2594.
- 399 8. Hsueh WC, Mitchell BD, Aburomia R, et al. Diabetes in the Old Order Amish:

400 characterization and heritability analysis of the Amish Family Diabetes Study. *Diabetes Care.*401 2000;23(5):595-601.

- 402 9. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a
- 403 dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose
- 404 tolerance test in patients with type 2 diabetes. *J Clin Endocrinol Metab.* 2006;91(11):4612-
- 405 4619.

- 406 10. D'Alessio D. The role of dysregulated glucagon secretion in type 2 diabetes. *Diabetes Obes*407 *Metab.* 2011;13 Suppl 1:126-132.
- 408 11. Haedersdal S, Andersen A, Knop FK, Vilsboll T. Revisiting the role of glucagon in health,
- diabetes mellitus and other metabolic diseases. *Nat Rev Endocrinol.* 2023;19(6):321-335.
- 410 12. Brooks EP, Sussel L. Not the second fiddle: alpha cell development, identity, and function in
 411 health and diabetes. *J Endocrinol.* 2023;258(2).
- 13. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves
- 413 model-assessed beta-cell function in patients with type 2 diabetes. *J Clin Endocrinol Metab.*
- 414 2005;90(8):4888-4894.
- 14. Mari A, Scherbaum WA, Nilsson PM, et al. Characterization of the influence of vildagliptin on
- 416 model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia. J
- 417 *Clin Endocrinol Metab.* 2008;93(1):103-109.
- 418 15. Alsalim W, Goransson O, Carr RD, et al. Effect of single-dose DPP-4 inhibitor sitagliptin on
- 419 beta-cell function and incretin hormone secretion after meal ingestion in healthy volunteers
- 420 and drug-naive, well-controlled type 2 diabetes subjects. *Diabetes Obes Metab.*
- 421 2018;20(4):1080-1085.
- 422 16. Anderwald C, Gastaldelli A, Tura A, et al. Mechanism and effects of glucose absorption
- 423 during an oral glucose tolerance test among females and males. *J Clin Endocrinol Metab.*424 2011;96(2):515-524.
- 425 17. Kahn SE, Lachin JM, Zinman B, et al. Effects of rosiglitazone, glyburide, and metformin on
 426 beta-cell function and insulin sensitivity in ADOPT. *Diabetes*. 2011;60(5):1552-1560.
- 427 18. Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes,
- 428 2022. A Consensus Report by the American Diabetes Association (ADA) and the European
- 429 Association for the Study of Diabetes (EASD). *Diabetes Care*. 2022;45(11):2753-2786.

- 430 19. Abdul-Ghani M, Puckett C, Adams J, et al. Durability of Triple Combination Therapy Versus
- 431 Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT.
- 432 *Diabetes Care*. 2021;44(2):433-439.
- 433 20. Chung WK, Erion K, Florez JC, et al. Precision Medicine in Diabetes: A Consensus Report
- 434 From the American Diabetes Association (ADA) and the European Association for the Study
- 435 of Diabetes (EASD). *Diabetes Care.* 2020;43(7):1617-1635.

1	Supplementary Appendix
2	
3	Acute pharmacodynamic responses to sitagliptin:
4	Drug-induced increase in early insulin secretion in oral glucose tolerance test.
5	
6	Amber L. Beitelshees PharmD ¹ Elizabeth A. Streeten MD ¹
7	Zhinous Shahidzadeh Yazdi MD ¹ Hilary B. Whitlatch MD ¹ Braxton D. Mitchell PhD ¹
8	Alan R. Shuldiner MD ¹ May E. Montasser PhD ¹ Simeon I. Taylor MD ¹
9	
10	¹ Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of
11	Maryland School of Medicine, Baltimore, MD 21201, USA
12	² Diabetes, Endocrinology, and Obesity Branch, National institute of Diabetes and Digestive and
13	Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
14	
15	Correspondence
16	Simeon I. Taylor, MD, PhD, Department of Medicine, University of Maryland School of Medicine,
17	Baltimore, MD 21201, USA
18	Email: staylor2@som.umaryland.edu
19	
20	Funding information
21	American Diabetes Association (1-16-ICTS-112) and National Institute of Diabetes and
22	Digestive and Kidney Disease (R01DK130238, T32DK098107, and P30DK072488)
23	

24 Table of Contents

25	1 Exclusion criteria	р. З
26	2 Oral glucose tolerance tests (OGTTs)	p. 4
27	3 Clinical chemistry	p. 5
28	TABLE S1. Demographics and baseline characteristics of study population	р. 6
29 30	TABLE S2. Effect of sitagliptin on T30:T60 ratios for glucose and insulin: data stratified based on self-identified sex.	p. 7
31 32	TABLE S3. Association of self-identified sex with areas-under-the-curve (AUC) for glucose in oral glucose tolerance test.	p. 8
33	FIGURE S1. CONSORT diagram summarizing disposition of research participants	р. 9
34 35	FIGURE S2. Inter-individual variation in effects of sitagliptin on T30:T60 ratios for glucose and insulin	p. 11
36	FIGURE S3. Association of age with responses to sitagliptin	p. 12
37	FIGURE S4. Association of age with responses to sitagliptin	р. 13
38 39	FIGURE S5. Correlation of pharmacodynamic effects of sitagliptin with pharmacodynamic effect exenatide	p. 14
40	4 References	p. 15

41 1 | Exclusion Criteria

- 42 Known allergy to exenatide
- History of diabetes, random glucose >200 mg/dL, or HbA1c > 6.5%
- Significant cardiac, hepatic, pulmonary, or renal disease or other diseases that the
- 45 investigator judged would make interpretation of the results difficult or increase the risk of
- 46 participation
- 47 Seizure disorder
- Pregnant by self-report or known pregnancy within 3 months of the start of study
- 49 Currently breast feeding or breast feeding within 3 months of the start of the study
- Estimated glomerular filtration rate <60 mL/min/1.73m²
- 51 Hematocrit <35%
- 52 Liver function tests greater than 2 times the upper limit of normal
- 53 Abnormal TSH
- History of pancreatitis or pancreatic cancer. Personal or family history of medullary
- 55 carcinoma of the thyroid.

- 56 2 | Oral glucose tolerance tests (OGTTs)
- 57 After an overnight fast, participants were transported to the Amish Research Clinic where
- 58 OGTTs were performed as described previously (1). Briefly, glucose (75 g, p.o.) was
- administered; blood samples were obtained at the following seven time points: 0, 30, 60, 90,
- 120, 150, and 180 min. Sitagliptin (100 mg, p.o.) was administered 2 hrs prior to the second
- 61 OGTT. Plasma levels of glucose and insulin were measured in blood samples for all seven time
- 62 points. Plasma levels of intact GLP1, total GIP, and glucagon were measured in blood samples
- 63 for the first three time points (0, 30, and 60 min).

65 3 | Clinical Chemistry

66 Screening blood samples were obtained by a research nurse during home visits and collected in 67 test tubes as appropriate for each assay: EDTA anticoagulant (purple top tube) for measurement of hematocrit and HbA1c; heparin anticoagulant (green top tube) for 68 measurement of TSH; gray top tubes containing sodium fluoride and potassium oxalate for 69 70 measurement of fasting plasma glucose; red top tube for collecting serum samples. After 71 placing gray, purple, and green top tubes on ice, blood samples were transported to the clinical 72 laboratory at the Amish Research Clinic (maximum transport time, 2 hours). After centrifugation (3300 rpm for 10 min), plasma/serum was sent on the same day to Quest Diagnostics for assay. 73 74 Blood samples for OGTTs were collected in EDTA-containing purple top tubes for measurement 75 of plasma insulin and in EDTA/oxalate-containing gray top tubes for measurement of plasma 76 glucose. Fifty µL of aprotinin solution (20,000 KIU/mL) was added per mL blood for glucagon 77 assays. A DPP4 inhibitor (Millipore) was added to plasma samples for assays of GLP1 and GIP at a concentration of 10 µL DPP4 inhibitor per mL blood. Glucose was measured in duplicate 78 79 using a YSI glucose analyzer. Insulin was assayed in duplicate following the manufacturer's directions using reagents in kits (#10-1113-01) purchased from Mercodia Inc. The following kits 80 81 were used for assays of other peptides: intact GLP1 (Millipore #EGLP-35K), total GIP (Millipore 82 #EXHGIP-54K), and glucagon (Mercodia #10-1271-01).

Mean ± SEM (range)	Males	Females	Total
N (sample size)	27	20	47
Age (years)	44.3 ± 2.2	51.8 ± 2.2	47.5 ± 1.6
BMI (kg/m²)	27.5 ± 0.7	28.7 ± 0.8	28.0 ± 0.5
HbA1c (%)	5.49 ± 0.07	5.59 ± 0.07	5.53 ± 0.05
Serum creatinine (mg/dL)	0.90 ± 0.02	0.74 ± 0.02	0.83 ± 0.02
eGFR (mL/min/1.73 m ²)	101.0 ± 2.5	94.1 ± 3.6	98.0 ± 2.1
Hematocrit (%)	43.8 ± 0.5	39.0 ± 0.5	41.8 ± 0.5
Aspartate amino transferase (U/L)	18.5 ± 0.9	17.4 ± 0.9	18.0 ± 0.6
Alanine amino transferase (U/L)	20.7 ± 1.7	17.3 ± 1.2	19.3 ± 1.0
TSH (mIU/L)	1.82 ± 0.20	1.81 ± 0.22	1.82 ± 0.14

Table S1. Demographics and baseline characteristics of study population

86 **TABLE S2. Effect of sitagliptin on T30:T60 ratios for glucose and insulin: data stratified**

based on self-identified sex. The magnitude of drug effects were calculated by dividing the

T30:T60 ratio during the sitagliptin OGTT by the corresponding value for the control OGTT.

89 Data are expressed as means ± SEM for 47 participants (27 males and 20 females). P-values

- 90 were calculated using two-tailed Student's t-test for paired data for the T30:T60 ratio for glucose
- 91 and the log(T30:T60 ratio for insulin).

92

Effect of sitagliptin	Males	Females	p-value
T30:T60 ratio (glucose)	1.26 ± 0.08	1.16 ± 0.06	0.36
T30:T60 ratio (insulin)	2.44 ± 0.82	1.46 ± 0.26	0.35
Ν	27	20	

94 TABLE S3. Association of self-identified sex with areas-under-the-curve (AUC) for

95 glucose in oral glucose tolerance test. Areas-under-the-curve for glucose and insulin were

- calculated using the trapezoidal rule. Data are presented as means ± SEM. p-values were
- 97 calculated using two-tailed Student's t-test for either unpaired (association with sex) or paired
- 98 data (effect of sitagliptin).

99

100 A. Association with sex

AUC	Treatment	Males	Females	p-value (for assoc. with sex)
Glucose	Control	2393 ± 72	2673 ± 94	0.02
Glucose	Sitagliptin	2181 ± 66	2465 ± 94	0.01
Insulin	Control	526 ± 45	666 ± 52	0.06
Insulin	Sitagliptin	501 ± 48	670 ± 72	0.05
Ν		27	20	

101

102 B. Effect of sitagliptin

AUC	Sex	Control	Sitagliptin	p-value (for effect of sitagliptin)
Glucose	Male	2393 ± 72	2181 ± 66	0.0002
Glucose	Female	2673 ± 94	2465 ± 94	8.3x10 ⁻¹⁰
Insulin	Male	526 ± 45	501 ± 48	0.61
Insulin	Female	666 ± 52	670 ± 72	0.95
Ν		27	20	

104 Figure S1. CONSORT diagram summarizing disposition of research participants. Seventy-105 one individuals underwent screening for the clinical trial between August, 2016 – November, 106 2018. Twelve enrollees were excluded for the following reasons (Fig. S1): low hematocrit (N=1), 107 abnormal TSH levels (N=5), abnormal liver function tests (N=1), family history of medullary 108 carcinoma of the thyroid (N=1), primary hyperparathyroidism (N=1), low eGFR (N=1), poor 109 venous access (N=1), and treatment with warfarin (N=1). Thus, 59 individuals were judged to be eligible for the clinical trial. Three individuals changed their minds and withdrew from the study 110 after providing informed consent but before undergoing an intravenous glucose tolerance test; 111 112 technical challenges with establishing venous access led to withdrawal of an additional participant. Fifty-five participants completed two oral glucose tolerance tests. Eight individuals 113 were excluded from the database because of missing data. Thus, data from 47 individuals 114 comprised the final database for the analyses. There were 13 reported adverse events of mild 115 116 severity. One participant reported feeling light-headed or "dizzy". There were six events in which a participant's plasma glucose (determined using a glucometer) was <70 mg/dL during the 117 118 course of an OGTT. Four participants reported headaches; one reported diarrhea; and one 119 reported nausea.

120

122 FIGURE S1. CONSORT Diagram

123



FIGURE S2. Indices for the effects of sitagliptin were calculated as the ratios of T30:T60 ratio from the sitagliptin OGTT divided by the corresponding ratio from the control OGTT. Analyses were conducted on logarithmically transformed ratios of drug effects for sitagliptin on glucose (panel A) and insulin (panel B). The graphs depict the numbers of individuals whose log(drug effects) fall into the ranges depicted on the respective x-axes.

131



135 FIGURE S3. Association of age with responses to sitagliptin. This Figure presents an 136 analysis of associations of age with data on T30:T60 ratios for glucose (panels A-C) and insulin 137 (panels D-F). Data for males and females are depicted by black circles or gray squares, respectively. Data for T30:T60 ratios for glucose are plotted on a linear scale; data for T30:T60 138 139 ratios for insulin are plotted on a logarithmic scale. Each panel includes the least squares linear fit to the data. Correlation coefficients (r) were calculated using the data corresponding to 140 T30:T60 ratios for glucose (panels A and B) or logarithms of the T30:T60 ratios for insulin 141 (panels D and E). The drug effect for T30:T60 ratio for glucose was calculated as the ratio of the 142 143 T30:T60 ratio for glucose in the control OGTT divided by the T30:T60 ratio in the sitagliptin OGTT (panel C). The drug effect for T30:T60 ratio for insulin was calculated as the difference 144 when the T30:T60 ratio for insulin in the sitagliptin OGTT was subtracted from the T30:T60 ratio 145

in the control OGTT (panel F). 146





150 FIGURE S4. Association of BMI with responses to sitagliptin. This Figure presents an 151 analysis of associations of BMI with data on T30:T60 ratios for glucose (panels A-C) and insulin 152 (panels D-F). Data for males and females are depicted by black circles or gray squares, respectively. Data for T30:T60 ratios for glucose are plotted on a linear scale; data for T30:T60 153 154 ratios for insulin are plotted on a logarithmic scale. Each panel includes the least squares linear fit to the data. Correlation coefficients (r) were calculated using the data corresponding to 155 T30:T60 ratios for glucose (panels A and B) or logarithms of the T30:T60 ratios for insulin 156 (panels D and E). The drug effect for T30:T60 ratio for glucose was calculated as the ratio of the 157 158 T30:T60 ratio for glucose in the control OGTT divided by the T30:T60 ratio in the sitagliptin OGTT (panel C). The drug effect for T30:T60 ratio for insulin was calculated as the difference 159 when the T30:T60 ratio for insulin in the sitagliptin OGTT was subtracted from the T30:T60 ratio 160 161 in the control OGTT (panel F).



162

164 FIGURE S5. Correlation of pharmacodynamic effects of sitagliptin with

pharmacodynamic effects of exenatide. The effect of sitagliptin on log(T30:T60 for insulin) is

plotted as a function of the effect of exenatide on log(1st phase insulin secretion) is plotted in the

- upper panel. The effect of sitagliptin on T30:T60 for glucose is plotted as a function of the effect
- 168 of exenatide on the glucose disappearance rate is plotted in the lower panel. Data on
- 169 pharmacodynamic effects of exenatide are based on data from the parent clinical trial with
- 170 exenatide [REF]. Correlation coefficients were calculated using software provided in Microsoft
- 171 EXCEL.



Sitagliptin v. Exenatide (Gluc Tolerance)



174 **REFERENCES**

- 175 1. Hsueh, W. C., Mitchell, B. D., Aburomia, R., Pollin, T., Sakul, H., Gelder Ehm, M. *et al.*
- 176 (2000) Diabetes in the Old Order Amish: characterization and heritability analysis of the
- Amish Family Diabetes Study Diabetes Care **23**, 595-601 10.2337/diacare.23.5.595